Afr J Reprod Health. 2026 Apr 28;30(8):44-52. doi: 10.29063/ajrh2026/v30i8.5.
ABSTRACT
This study investigates the effects of elevit supplementation on liver function and maternal-neonatal outcomes in HBsAg-positive pregnant women. A total of 160 participants were divided into a control group (routine care) and an observation group (routine care plus elevit). Liver function markers (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase) were measured in early, mid, and late pregnancy. Maternal complications and neonatal outcomes were recorded, along with adverse reactions. No significant differences in liver enzymes were noted in early pregnancy. However, the observation group showed elevated alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase in mid and late pregnancy, indicating possible liver damage from prolonged elevit use. Despite this, the observation group experienced lower rates of hypertensive disorders, gestational diabetes, intrahepatic cholestasis, postpartum hemorrhage, low birth weight, and preterm birth, as well as higher Apgar scores. Adverse effects were slightly more frequent but not statistically significant. These findings suggest that while elevit may mildly affect liver function, it potentially improves pregnancy outcomes in HBsAg-positive women.
PMID:42047092 | DOI:10.29063/ajrh2026/v30i8.5
